Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Immix Biopharma Inc (IMMX)

Immix Biopharma Inc (IMMX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 177,292
  • Shares Outstanding, K 33,578
  • Annual Sales, $ 0 K
  • Annual Income, $ -21,610 K
  • EBIT $ -24 M
  • EBITDA $ -24 M
  • 60-Month Beta 0.33
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 22.02

Options Overview Details

View History
  • Implied Volatility 126.59% (+7.59%)
  • Historical Volatility 96.14%
  • IV Percentile 28%
  • IV Rank 7.34%
  • IV High 1,427.58% on 09/09/25
  • IV Low 23.59% on 08/14/25
  • Expected Move (DTE 16) 0.80 (15.28%)
  • Put/Call Vol Ratio 12.83
  • Today's Volume 166
  • Volume Avg (30-Day) 380
  • Put/Call OI Ratio 0.47
  • Today's Open Interest 2,886
  • Open Int (30-Day) 2,780
  • Expected Range 4.43 to 6.03

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.16
  • Number of Estimates 1
  • High Estimate -0.16
  • Low Estimate -0.16
  • Prior Year -0.16
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.78 +38.36%
on 12/03/25
7.73 -32.34%
on 12/12/25
+0.98 (+23.06%)
since 11/28/25
3-Month
1.99 +162.17%
on 10/06/25
7.73 -32.34%
on 12/12/25
+3.14 (+150.24%)
since 09/30/25
52-Week
1.34 +290.30%
on 04/08/25
7.73 -32.34%
on 12/12/25
+2.87 (+121.61%)
since 12/30/24

Most Recent Stories

More News
Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

– Financing includes leading U.S. biotechnology institutional investors and mutual funds – LOS ANGELES, CA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”,...

IMMX : 5.23 (-0.95%)
Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

LOS ANGELES, CA, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today...

IMMX : 5.23 (-0.95%)
At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

– NXC-201 demonstrated a complete response (CR) rate of 75% (15/20) (at s/u IFE(-) level) by independent review committee – – In four out of five pending patients, MRD negativity in bone marrow...

IMMX : 5.23 (-0.95%)
Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch

- Former Chimerix (CMRX, acquired by Jazz for $935 million) Senior Commercial Leader Michael Grabow led Go-To-Market Strategy and Launch for rare disease therapeutic MODEYSO® - - Rare disease commercial...

IMMX : 5.23 (-0.95%)
Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025

- Oral presentation Sunday, December 7, at ASH 2025 - LOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the...

IMMX : 5.23 (-0.95%)
Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

LOS ANGELES, CA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis,...

IMMX : 5.23 (-0.95%)
Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting

Los Angeles, CA, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis,...

IMMX : 5.23 (-0.95%)
Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference

Los Angeles, CA, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell...

IMMX : 5.23 (-0.95%)
Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2

– On track for first FDA Biologics License Application (BLA) approved cell therapy in orphan indication relapsed/refractory AL Amyloidosis – Los Angeles, CA, Sept. 18, 2025 (GLOBE NEWSWIRE) --...

IMMX : 5.23 (-0.95%)
Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors

  – Dr. Chang led XOLAIR® from invention through FDA approval and commercialization, exceeding $5 billion in sales so far –  Los Angeles, CA, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma,...

IMMX : 5.23 (-0.95%)

Business Summary

Immix Biopharma Inc. is a biopharmaceutical company pioneering Tissue Specific Therapeutics (TM) targeting oncology and immuno-dysregulated diseases. Immix Biopharma Inc. is based in LOS ANGELES.

See More

Key Turning Points

3rd Resistance Point 5.59
2nd Resistance Point 5.48
1st Resistance Point 5.36
Last Price 5.23
1st Support Level 5.13
2nd Support Level 5.02
3rd Support Level 4.90

See More

52-Week High 7.73
Fibonacci 61.8% 5.29
Last Price 5.23
Fibonacci 50% 4.53
Fibonacci 38.2% 3.78
52-Week Low 1.34

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar